Evofem Biosciences, Inc. (EVFM)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Product sales, net | 4,825 | 845 | 4,496 | 4,160 |
| Research and development | - | - | 332 | 270 |
| Selling and marketing | 2,625 | 2,600 | 2,382 | 2,243 |
| General and administrative | 1,843 | 2,365 | 3,052 | 2,267 |
| Cost of goods sold | 755 | 365 | 869 | 769 |
| Amortization of intangible asset | 107 | - | - | - |
| Amortization of intangible asset | 100 | 223 | 301 | - |
| Research and development, net | 746 | -5,035 | - | - |
| Total operating expenses | 6,076 | 518 | 6,936 | 5,549 |
| Loss from operations | -1,251 | 327 | -2,440 | -1,389 |
| Other expense, net | 662 | 600 | 562 | 558 |
| Interest income | 2 | 8 | 3 | 6 |
| Gain on debt extinguishment, net | - | - | -143 | - |
| Loss on issuance of financial instruments | - | - | - | -25 |
| Change in fair value of financial instruments | 134 | 1,221 | 769 | 3,325 |
| Total other income (expense), net | -526 | 629 | 67 | 2,748 |
| Income (loss) before income tax expense | -1,777 | 956 | -2,373 | 1,359 |
| Income tax expense | 7 | - | -8 | 8 |
| Net income (loss) | -1,784 | 956 | -2,365 | 1,351 |
| Convertible and redeemable preferred stock deemed dividends | -1 | -3 | -5 | -47 |
| Net income (loss) attributable to common stockholders | -1,785 | 953 | -2,370 | 1,304 |
| Basic | 115,686,024 | 113,356,354 | 96,459,121 | 66,773,313 |
| Basic (note 2) | -0.02 | 0.01 | -0.02 | 0.02 |
| Diluted | 115,686,024 | 6,039,898,041 | 96,459,121 | 1,613,722,212 |
| Diluted (note 2) | -0.02 | - | -0.02 | - |